SBIR/STTR Research Award
Mimic Peptides of HIV1 Epitopes as Vaccines
Award amount
$299,994Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Mixture Sciences, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (Provided by Applicant): Despite current aggressive treatment
protocols based on powerful drug combinations, the incidence of HIV-1 infection
is increasing, from already very large numbers, mainly in developing countries
that can least afford these newer drug regimens. The objective of this proposal
combines the technologies of T cell immunobiology and synthetic peptide
chemistry in a strategy of antigen discovery and optimization to identify
individual candidate peptide sequence mimics for HIV-1 gag protein fragments as
starting points in the design of preventive and therapeutic vaccines.
Individual lines and clones of human cytotoxic T lymphocytes (CTL) having
relevant lytic specificity for HIV peptide pulsed target cells will be used to
screen very large combinatorial peptide libraries for peptide sequences that
best stimulate proliferative, cytokine release, or lytic responses by these CTL
clones. Candidate sequences deduced from each clonal scan will be synthesized
and each individually assessed for activity on the selecting clone. The most
effective peptide sequences will then be made available for ex vivo
immunogenicity assessments and for phase I/II toxicity/efficacy clinical
trials. Preliminary studies indicate that these library scans identify peptides
several orders of magnitude more effective than native peptide ligands used to
generate a particular T cell clone, and that these optimized superagonist
peptides are effective as vaccines, provoking strong T cell mediated immune
responses against native peptide ligands.
PROPOSED COMMERCIAL APPLICATION:
Not Available
Technology keywords
Not reported